CRL [NYSE]
Charles River Laboratories International, Inc.
IndexS&P 500 P/E26.29 EPS (ttm)8.62 Insider Own0.90% Shs Outstand50.82M Perf Week2.32%
Market Cap11.73B Forward P/E18.34 EPS next Y12.35 Insider Trans-14.06% Shs Float50.24M Perf Month4.14%
Income443.30M PEG1.85 EPS next Q2.60 Inst Own96.40% Short Float1.94% Perf Quarter-1.19%
Sales3.69B P/S3.18 EPS this Y5.60% Inst Trans0.81% Short Ratio1.95 Perf Half Y-32.79%
Book/sh52.10 P/B4.35 EPS next Y11.64% ROA6.20% Target Price286.36 Perf Year-44.38%
Cash/sh3.89 P/C58.26 EPS next 5Y14.24% ROE17.40% 52W Range203.37 - 460.21 Perf YTD-39.88%
Dividend- P/FCF34.64 EPS past 5Y18.70% ROI10.20% 52W High-50.79% Beta1.30
Dividend %- Quick Ratio1.10 Sales past 5Y16.10% Gross Margin37.40% 52W Low11.36% ATR9.37
Employees18600 Current Ratio1.30 Sales Q/Q6.40% Oper. Margin18.60% RSI (14)48.75 Volatility3.56% 3.65%
OptionableYes Debt/Eq1.13 EPS Q/Q23.70% Profit Margin12.00% Rel Volume1.44 Prev Close226.52
ShortableYes LT Debt/Eq1.13 EarningsAug 03 BMO Payout0.00% Avg Volume500.43K Price226.47
Recom1.70 SMA20-1.60% SMA500.22% SMA200-23.17% Volume719,166 Change-0.02%
Aug-04-22Downgrade Morgan Stanley Overweight → Equal-Weight $350 → $250
May-24-22Initiated Guggenheim Neutral
Apr-25-22Downgrade Jefferies Buy → Hold $370 → $280
Apr-07-22Initiated Stephens Overweight $377
Feb-17-22Upgrade Citigroup Neutral → Buy $400
Feb-17-22Reiterated UBS Buy $465 → $420
Feb-17-22Reiterated Morgan Stanley Overweight $465 → $430
Feb-17-22Reiterated Deutsche Bank Buy $409 → $350
Feb-17-22Reiterated BofA Securities Buy $445 → $400
Aug-05-21Resumed Credit Suisse Neutral $385
Dec-16-20Downgrade Citigroup Buy → Neutral $270 → $250
Sep-10-20Upgrade Jefferies Hold → Buy $254
Jul-01-20Upgrade BofA Securities Neutral → Buy $192
May-13-20Upgrade UBS Neutral → Buy $177 → $200
Apr-21-20Downgrade Jefferies Buy → Hold $139
Mar-27-20Upgrade Morgan Stanley Equal-Weight → Overweight $152
Mar-02-20Initiated Deutsche Bank Buy $190
Feb-18-20Upgrade Wolfe Research Peer Perform → Outperform
Jan-10-20Upgrade Goldman Neutral → Buy $143 → $179
Jan-08-20Initiated Wells Fargo Overweight $180
Aug-09-22 08:00AM  
Aug-03-22 10:27AM  
08:15AM  
07:00AM  
Aug-02-22 01:13PM  
Jul-29-22 06:43AM  
Jul-28-22 10:02AM  
Jul-27-22 10:02AM  
Jul-25-22 11:33AM  
Jul-11-22 11:23AM  
08:30AM  
Jul-07-22 06:15AM  
Jul-05-22 12:56PM  
Jun-28-22 01:08PM  
08:55AM  
08:00AM  
Jun-23-22 08:00AM  
Jun-21-22 09:30AM  
Jun-14-22 11:03AM  
Jun-13-22 08:00AM  
Jun-08-22 07:33AM  
Jun-06-22 08:00AM  
Jun-03-22 11:31AM  
09:40AM  
May-26-22 10:34AM  
May-25-22 03:57PM  
May-24-22 07:57AM  
May-16-22 11:47AM  
May-10-22 10:48AM  
May-04-22 11:42AM  
08:15AM  
07:00AM  
May-03-22 10:34AM  
Apr-28-22 07:09AM  
Apr-27-22 03:03PM  
10:24AM  
08:00AM  
Apr-13-22 04:30PM  
Apr-11-22 11:48AM  
08:54AM  
01:42AM  
Apr-07-22 08:00AM  
Apr-06-22 08:00AM  
Apr-05-22 09:31AM  
Mar-31-22 06:00AM  
Mar-28-22 11:31AM  
08:00AM  
Mar-27-22 02:18PM  
Mar-18-22 11:30AM  
Mar-16-22 02:30AM  
Mar-10-22 05:41AM  
Mar-09-22 08:48AM  
Feb-22-22 10:56AM  
Feb-19-22 06:55AM  
Feb-17-22 08:18AM  
08:16AM  
Feb-16-22 10:48AM  
08:15AM  
07:00AM  
Feb-15-22 10:19AM  
09:44AM  
Feb-11-22 11:09AM  
Feb-09-22 03:01PM  
Feb-08-22 08:11AM  
Feb-07-22 07:43AM  
Feb-04-22 04:33PM  
12:45PM  
Feb-03-22 08:00AM  
Feb-02-22 11:45AM  
Feb-01-22 08:23AM  
08:00AM  
Jan-27-22 09:38AM  
08:00AM  
Jan-26-22 09:38AM  
Jan-24-22 01:38PM  
09:38AM  
Jan-21-22 05:38PM  
09:38AM  
09:38AM  
Jan-20-22 08:30AM  
Jan-19-22 12:45PM  
09:00AM  
Jan-18-22 05:38PM  
Jan-11-22 07:00AM  
Jan-06-22 08:00AM  
Jan-04-22 01:38PM  
Dec-31-21 07:30AM  
Dec-27-21 10:38PM  
Dec-20-21 05:38AM  
Dec-17-21 05:38PM  
Dec-16-21 05:38PM  
09:38AM  
12:38AM  
Dec-15-21 09:38AM  
09:05AM  
05:18AM  
Dec-14-21 01:38PM  
Dec-08-21 07:38PM  
07:38PM  
05:38PM  
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 05Sale226.1320045,22720,766Aug 08 03:03 PM
MASSARO GEORGEDirectorMay 09Sale230.9617841,1104,677May 11 03:52 PM
Smith David RossCorporate Executive VP & CFOMar 03Option Exercise136.608,9651,224,59434,784Mar 04 04:13 PM
Smith David RossCorporate Executive VP & CFOMar 03Sale282.538,9652,532,92125,819Mar 04 04:13 PM
FOSTER JAMES CChairman, President and CEOFeb 23Option Exercise109.3420,2962,219,165235,318Feb 25 04:20 PM
FOSTER JAMES CChairman, President and CEOFeb 23Sale287.8320,2965,841,869215,022Feb 25 04:20 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 23Sale292.75395115,63619,852Feb 24 06:37 PM
FOSTER JAMES CChairman, President and CEOFeb 22Option Exercise144.6717,4362,522,466234,228Feb 23 04:49 PM
WALLMAN RICHARD FDirectorFeb 22Sale288.053,250936,1620Feb 23 04:07 PM
FOSTER JAMES CChairman, President and CEOFeb 22Sale288.6717,4365,033,328216,792Feb 23 04:49 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 22Sale290.83396115,17020,562Feb 23 04:44 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 18Option Exercise88.0574365,42122,418Feb 23 04:44 PM
WALLMAN RICHARD FDirectorFeb 18Sale297.502,800833,0003,250Feb 23 04:07 PM
WALLMAN RICHARD FDirectorFeb 18Sale295.001,150339,25017,679Feb 23 04:07 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 18Sale291.801,143333,52721,275Feb 23 04:44 PM
FOSTER JAMES CChairman, President and CEOFeb 15Sale315.4620,0006,309,137218,402Feb 17 04:41 PM
Girshick BirgitCorporate Executive VPSep 14Sale439.902,3441,031,12627,602Sep 15 11:11 AM
Girshick BirgitCorporate Executive VPSep 13Sale442.198135,81729,946Sep 15 11:11 AM
MASSARO GEORGEDirectorAug 31Option Exercise164.242,539417,0057,394Sep 01 02:29 PM
MASSARO GEORGEDirectorAug 31Sale442.482,5391,123,4574,855Sep 01 02:29 PM
Creamer Victoria LEVP & Chief People OfficerAug 16Option Exercise145.346,9171,005,33013,303Aug 17 03:01 PM
Creamer Victoria LEVP & Chief People OfficerAug 16Sale415.246,9172,872,2366,386Aug 17 03:01 PM